Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma
A Prospective, Multi-center, Single-arm Clinical Study of Sintilimab Injection Combined With Concurrent Radiotherapy and Chemotherapy in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma (IMCORT)
Sponsor: Affiliated Hospital of Southwest Medical University
A PHASE2 clinical study on Locally Advanced Esophageal Squamous Cell Carcinoma, this trial is ongoing. The trial is conducted by Affiliated Hospital of Southwest Medical University and has accumulated 5 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Nov 2022 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Nov 2022 [monthly]
Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
First recorded
Oct 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Affiliated Hospital of Southwest Medical University
- Chongqing Three Gorges Central Hospital
- First Affiliated Hospital Xi'an Jiaotong University
- General Hospital of Ningxia Medical University
- Sichuan Cancer Hospital and Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .